<var id="thfl3"></var>
<var id="thfl3"></var>
<var id="thfl3"><video id="thfl3"><thead id="thfl3"></thead></video></var><menuitem id="thfl3"></menuitem>
<var id="thfl3"></var><cite id="thfl3"></cite><var id="thfl3"><video id="thfl3"></video></var>
<var id="thfl3"><span id="thfl3"></span></var><cite id="thfl3"><span id="thfl3"><var id="thfl3"></var></span></cite>
<ins id="thfl3"><span id="thfl3"><menuitem id="thfl3"></menuitem></span></ins>
<var id="thfl3"></var>
COVID-19

Guidance for medicine developers and other stakeholders on COVID-19

The European Medicines Agency (EMA) is providing guidance for medicine developers and pharmaceutical companies to help speed up medicine and vaccine development and approval for COVID-19, and on how they should address the?regulatory challenges?arising from?the COVID-19 pandemic.

In this section: guidance for COVID-19 medicines

?

Research and development

Guidance for developers of COVID-19 medicines in the research and development phase.

Evaluation and marketing authorisation

Guidance for developers of COVID-19 medicines preparing to submit data to EMA for evaluation.

Post authorisation

Guidance on post-authorisation monitoring of COVID-19 medicines.

?

Clinical trials affected by the pandemic

Guidance is available for clinical-trial sponsors on how they should adjust the management of clinical trials and participants during the COVID-19 pandemic.?This covers concrete changes and protocol deviations for dealing with extraordinary situations, such as the need for isolating participants, limited access to public spaces and the reallocation of healthcare professionals:

Guidance is also available on the?actions?that?sponsors?of affected clinical trials should take to help ensure the integrity of their studies and the interpretation of the study results while safeguarding the safety of trial participants as a first priority.

    EMA revised this guidance on 29 June 2020 following a four-week public consultation.

    In line with this guidance, EMA will be flexible and pragmatic during the assessment of affected clinical trial data submitted to the Agency as part of marketing authorisation applications.

    For inspectors, guidance on how to initiate and conduct good clinical practice inspections remotely during the pandemic is also available:

      Regulatory expectations and flexibility (human medicines)

      Guidance is available for companies responsible for human medicines on adaptations to the regulatory framework to address challenges arising from the COVID-19 pandemic, with a particular focus on crucial medicines for use in COVID-19 patients:

        The guidance covers:

        Companies should send ECMP notifications for centrally authorised products to covid-ecmp@ema.europa.eu?using this?template:

          Companies should note that some of the measures described in the guidance are reserved for crucial medicines used for treating COVID-19 patients.

          The guidance?was agreed by EMA, the European Commission, the European medicines regulatory network and endorsed by the EU Executive Steering Group on Shortages of Medicines Caused by Major Events.?

          Additional guidance is available for?marketing authorisation holders on submitting COVID-19-related ICSRs to EudraVigilance, including on the?correct use of COVID-19-related terms of version 23.0 of the Medical Dictionary for Regulatory Activities (MedDRA):

          Regulatory expectations and flexibility (veterinary medicines)

          Guidance is available for companies responsible for veterinary?medicines on adaptations to the regulatory framework to address challenges arising from the COVID-19 pandemic:

          The guidance covers:

          The guidance was agreed by EMA, the European Commission, the European medicines regulatory network and endorsed by the EU Executive Steering Group on Shortages of Medicines Caused by Major Events. It was first published on 30 April 2020.

          The guidance was updated on 1 July 2020 to cover pharmacovigilance inspections.

          Further updates to this guidance are possible?as the pandemic develops.

          Topics

          How useful was this page?

          Add your rating
          Average
          16 ratings
          1 rating
          2 ratings
          2 ratings
          3 ratings
          欧美大屁股XXXX,免费1级做爰片L在线观看,在线观看国产高清免费不卡,a 成 人小说网站在线观看